AVANZANITE
LIVE

Serial Number

79321187

Owner

Avanzanite Holding B.V.

Attorney

Alexander Lazouski

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

AVANZANITE Trademark

Serial Number: 79321187 • Registration: 7014563

AVANZANITE is a trademark filed by Avanzanite Holding B.V. on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Avanzanite Holding B.V. (2 trademarks)

Strawinskylaan 3051

Entity Type: 98

Adam Andrzej Plich (2 trademarks)

Rubensstraat 62 III

Entity Type: 01

Trademark Details

Filing Date

August 2, 2021

Registration Date

April 4, 2023

Published for Opposition

January 17, 2023

Goods & Services

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; medical and veterinary pharmaceutical preparations for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; biotechnological preparations for medical, pharmaceutical and veterinary purposes, namely, biotechnological preparations for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; biological preparations for medical, pharmaceutical and veterinary purposes, namely, biological preparations for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; biological implants, namely, a vital processed human or animal connective tissue; chemical preparations for medical, pharmaceutical and veterinary purposes, namely, preparations for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; chemico pharmaceutical preparations, namely, preparations for pharmaceutical or medical purposes for the treatment of viral, infectious, parasitic, metabolic, endocrine, nutritional, musculoskeletal, cardiovascular, cardiopulmonary, circulatory system diseases, genitourinary, pregnancy, childbirth, puerperium and perinatal period disorders, developmental anomalies, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, otolaryngological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, behavioural, neurodevelopmental, sleep-wake and immune system related diseases and disorders; sanitary preparations for medical purposes; dietetic foods and substances adapted for medical or veterinary use, namely, dietetic preparations adapted for medical purposes, dietetic foods adapted for medical use, dietetic sugar substitutes for medical use; dietary supplements for human beings and animals; medical plasters, materials for dressings, namely, sterilized dressing, bandages for dressings, wadding for dressings; disinfectants; preparations for destroying vermin

Filing History

CHANGE OF OWNER RECEIVED FROM IB
Dec 11, 2025 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 14, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 21, 2023 FICS
FINAL DISPOSITION PROCESSED
Jul 21, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 4, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 4, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 4, 2023 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 20, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 1, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 1, 2023 OPNR
NOTIFICATION PROCESSED BY IB
Jan 24, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 17, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jan 17, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 4, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 4, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 28, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 13, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 12, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 12, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 12, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 12, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 1, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 1, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 1, 2022 TROA
REFUSAL PROCESSED BY IB
Jul 5, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 10, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 9, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 7, 2022 RFCR
NON-FINAL ACTION WRITTEN
May 6, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 5, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 1, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 30, 2021 REPR